NT Hepatitis B Advanced Management and Prescribing

NT Hepatitis B Turning Point

The Northern Territory carries Australia’s heaviest hepatitis B burden, with overall prevalence of 1.73% and rates reaching 6% among First Nations people, driven by an ancient sub-genotype C4 that circulates nowhere else and progresses aggressively to liver cancer and cirrhosis.

Recent years have delivered striking results. Between the first six months of 2022 and 2024 diagnoses almost tripled, yet mortality has fallen more sharply in the NT than anywhere else since 2011. The Hep B PAST partnership, running from 2018 to 2023, systematically documented hepatitis B status for over 40,000 First Nations residents across 66 remote clinics, pushing diagnosis coverage from under 12% to 99.9%, care engagement to 86%, and treatment uptake to 24%—surpassing every national and global benchmark.

That success now creates new pressure. A 2025 retrospective cohort study of 783 C4 patients found 16% already had cirrhosis and another 6% significant fibrosis. Only 25% were on antivirals; current Australian guidelines would treat just 7% more, but broader World Health Organization criteria incorporating fibrosis, viral load and the territory’s 29% diabetes prevalence raise eligibility to around 50%. With 70% of NT cases in Aboriginal people and hepatocellular carcinoma incidence five to six times higher than in non-Indigenous Australians, the window for preventing avoidable deaths is narrowing.

Non-obvious tensions abound. The very programs that tripled diagnoses rely on community co-design, kinship-based mentoring and in-language resources—models now cited in the draft Fourth National Hepatitis B Strategy 2023–2030 for national scaling. Yet remote primary care must absorb advanced management without specialist backup across 1.3 million square kilometres. Comorbid metabolic disease further accelerates fibrosis, meaning antiviral prescribing cannot be decoupled from integrated chronic-care pathways. Australia as a whole lags its 2030 elimination targets; the NT’s experience shows both what is possible and what extra workforce capacity will cost if the gains are not consolidated.